Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Phase III Acute Coronary Syndrome
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7484
- Registration Number
- NCT00831441
- Locations
- 🇺🇸
Central Jersey Medical Research Center, Elizabeth, New Jersey, United States
🇺🇸Delmarva Heart Research Foundation, Salisbury, Maryland, United States
🇺🇸Washington University School Of Medicine, St. Louis, Missouri, United States
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 222
- Registration Number
- NCT00787150
- Locations
- 🇯🇵
Pfizer Investigational Site, Kumamoto, Japan
Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5614
- Registration Number
- NCT00643201
- Locations
- 🇺🇸
Pasadena Center For Medical Research, St. Petersburg, Florida, United States
🇺🇸Great Falls Clinic, Llp, Great Falls, Montana, United States
🇺🇸Infectious Disease Of Indiana Psc, Carmel, Indiana, United States
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2711
- Registration Number
- NCT00633893
- Locations
- 🇺🇸
Mercury Street Medical Group, Pllc, Butte, Montana, United States
🇺🇸Piedmont Healthcare/Research, Statesville, North Carolina, United States
🇺🇸William Beaumont Hospital, Royal Oak, Michigan, United States
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6421
- Registration Number
- NCT00496769
- Locations
- 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Kaiser Permanente Medical Center, West Los Angeles, Los Angeles, California, United States
🇺🇸Southwest Heart, Tucson, Arizona, United States
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
- Conditions
- Interventions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6758
- Registration Number
- NCT00457002
- Locations
- 🇺🇸
Pulmonary & Critical Care Of Atlanta, Atlanta, Georgia, United States
🇺🇸Atlanta Institute For Medical Research, Inc, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3221
- Registration Number
- NCT00452530
- Locations
- 🇬🇧
Local Institution, Epsom, Surrey, United Kingdom
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5407
- Registration Number
- NCT00423319
- Locations
- 🇺🇸
Shrock Orthopedic Research, Ft. Lauderdale, Florida, United States
🇺🇸Orthoarkansas, P.A., Little Rock, Arkansas, United States
🇺🇸Pab Clinical Research, Brandon, Florida, United States
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20976
- Registration Number
- NCT00412984
- Locations
- 🇺🇸
David Charles Mishkel, Md, Pa, Boca Raton, Florida, United States
🇺🇸Heart Care Center, P.C., East Syracuse, New York, United States
🇺🇸Elkhart Clinic, Llc, Elkhart, Indiana, United States
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT00320255
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mount Sinai School Of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.